A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus

Inclusion Criteria: * Adult patients, 18 to 65 years of age, inclusive * Type 2 diabetes mellitus according to WHO criteria diagnosed for at least 3 months prior to screening * On stable dose of metformin for at least 2 months prior to screening * Fasting plasma glucose during the screening period \</= 240 mg/dL * Hemoglobin A1c (HbA1c) levels at screening \>/= 6.5% and \</= 10.5% * Evidence of insulin secretory capacity at screening * Body mass index (BMI) 27 to 42 kg/m2, inclusive * Females of child-bearing potential and males with female partners of child-bearing potential must agree to use effective contraception as defined by protocol Exclusion Criteria: * Type 1 diabetes * Acquired or secondary forms of diabetes such as those resulting from pancreatic surgery/injury, cystic fibrosis related diabetes * History of acute metabolic complications such as diabetic ketoacidosis or state of hyperosmolar hyperglycemia * Evidence or history of clinically significant diabetic complications such as clinically severe diabetic peripheral neuropathy, clinically significant nephropathy as judged by the investigator, or pre-proliferative/proliferative diabetic retinopathy as judged by the investigator * History of severe symptomatic hypoglycemia (requiring assistances of a third party) within 6 months prior to screening * History or presence of clinically significant concomitant disease or disorder * Hemoglobin level below the lower limit of reference range at screening * Pregnant or lactating women * History of anaphylaxis or severe systemic hypersensitivity or allergic reactions